دورية أكاديمية
Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles
| العنوان: | Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles |
|---|---|
| المؤلفون: | Yu, Ting, Zhao, Shengnan, Li, Ziqiang, Wang, Yi, Xu, Bei, Fang, Dailong, Wang, Fazhan, Zhang, Zhi, He, Lili, Song, Xiangrong, Yang, Jian |
| المصدر: | Yu, T., S. Zhao, Z. Li, Y. Wang, B. Xu, D. Fang, F. Wang, et al. 2016. “Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles.” International Journal of Molecular Sciences 17 (12): 1977. doi:10.3390/ijms17121977. http://dx.doi.org/10.3390/ijms17121977Test. |
| بيانات النشر: | MDPI, 2016. |
| سنة النشر: | 2016 |
| المجموعة: | HMS Scholarly Articles |
| مصطلحات موضوعية: | PLGA nanoparticles, antihypertensive peptide, oral administration, sustained release, continuously antihypertensive effect |
| الوصف: | Hypertension has become a significant global public health concern and is also one of the most common risk factors of cardiovascular disease. Recent studies have shown the promising result of peptides inhibiting angiotensin converting enzyme (ACE) in lowering the blood pressure in both animal models and humans. However, the oral bioavailability and continuous antihypertensive effectiveness require further optimization. Novel nanoparticle-based drug delivery systems are helpful to overcome these barriers. Therefore, a poly-(lactic-co-glycolic) acid nanoparticle (PLGANPs) oral delivery system, of the antihypertensive small peptides Val-Leu-Pro-Val-Pro (VLPVP, VP5) model, was developed in this study and its antihypertensive effect was investigated in spontaneously hypertensive rats (SHRs) for the first time. The obtained VP5 nanoparticles (VP5-NPs) showed a small particle size of 223.7 ± 2.3 nm and high entrapment efficiency (EE%) of 87.37% ± 0.92%. Transmission electronic microscopy (TEM) analysis showed that the nanoparticles were spherical and homogeneous. The optimal preparation of VP5-NPs exhibited sustained release of VP5 in vitro and a 96 h long-term antihypertensive effect with enhanced efficacy in vivo. This study illustrated that PLGANPs might be an optimal formulation for oral delivery of antihypertensive small peptides and VP5-NPs might be worthy of further development and use as a potential therapeutic strategy for hypertension in the future. |
| نوع الوثيقة: | Journal Article |
| اللغة: | English |
| تدمد: | 1422-0067 |
| العلاقة: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187777/pdfTest/; International Journal of Molecular Sciences |
| DOI: | 10.3390/ijms17121977 |
| الوصول الحر: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:29738921Test |
| حقوق: | open URL: http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAATest |
| رقم الانضمام: | edshld.1.29738921 |
| قاعدة البيانات: | Digital Access to Scholarship at Harvard (DASH) |
Full Text Finder | تدمد: | 14220067 |
|---|---|
| DOI: | 10.3390/ijms17121977 |